Business
finnCap publishes initiation research
finnCap publishes initiation research.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 8102U Evgen Pharma PLC 02 April 2019 \n\n \n\n\n\n\nFor immediate release\n\n\n2 April 2019\n\n\n\n\n \nRNS REACH\n \nEvgen Pharma plc \n (\"Evgen\" or \"the Company\")\n \nfinnCap publishes initiation research\nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that finnCap, the Company's broker, has this morning initiated research on the Company. The research report is available to all by registering at finnCap's research portal: https://researchlibrary.finncap.com/\nThe report provides a comprehensive introduction to Evgen and its proprietary sulforaphane-based technology platform along with discussing in detail the Company's recent positive Phase II data in metastatic breast cancer and ongoing Phase II trial in subarachnoid haemorrhage. \n \n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\nwww.evgen.com\n \n\n\nc/o +44 (0) 20 7466 5000\n\n\n\n\nfinnCap\nGeoff Nash, Teddy Whiley (Corporate Finance)\nAlice Lane, Manasa Patil (ECM)\nwww.finncap.com\n \n\n\n +44 (0) 20 7220 0500 \n\n\n\n\nWG Partners LLP\nNigel Barnes, Claes Spång\n \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nBuchanan\nMark Court, Sophie Wills, Tilly Abraham\[email protected]\n \n\n\n +44 (0) 20 7466 5000\n\n\n\n\nNotes for editors:\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \nThe Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. \nFor further information, please visit: www.evgen.com\n \n\nThis information is provided by RNS, the news servic...